Bicycle Therapeutics plc Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount
Bicycle Therapeutics plc (BCYC) had Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount of $0 as of 2019-12-31, per its 10-K filed 2020-03-10.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount · last filed 2020-03-10
- 2019-12-31: Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount $0.00.
- 2019-09-30: Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount $0.00.
- 2019-06-30: Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount $0.00.
- 2018-12-31: Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount $0.00.
| Period end | Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount |
|---|---|
| 2019-12-31 | $0.00 10-K · filed 2020-03-10 |
| 2019-09-30 | $0.00 10-Q · filed 2019-11-07 |
| 2019-06-30 | $0.00 10-Q · filed 2019-08-08 |
| 2018-12-31 | $0.00 10-K · filed 2020-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |